Dandan Tian and Zheyi Hu Pages 808 - 817 ( 10 )
Cytochromes P450 enzymes, especially CYP3A4, are responsible for metabolizing a broad range of anticancer drugs. Combination therapy is common in patients with cancer, which may cause potential drug drug interactions (DDIs) leading to increased risk of side-effects/toxicity or decreased effectiveness. The review summarizes CYP3A4-mediated DDIs, with anticancer drugs as CYP3A4 substrates or modulators, in clinical trials during cancer therapy and aims to increase clinicians' awareness to take caution to reduce the risk.
Anticancer drugs, cytochromes P450 (CYP) enzymes, drug-drug interactions, pharmacokinetics.
Department of Clinical Pharmacy, University of Tennessee Health Science Center, College of Pharmacy, 881 Madison Ave., Memphis, TN, 38163, USA.